Fremont
Upstream process development in a high throughput automated bioreactor system.
Search
Kobe
The Kobe Pharma Research Institute takes part in the global research and development activities for human pharmaceuticals.
Koropi
For more than 45 years, the company has been producing pharmaceuticals in its production facility in Koropi, Greece.
Rare Diseases: Rare but not alone
We are committed to listen and learn from patients with rare diseases to deliver breakthrough therapies.
Building Successful Partnerships in Animal Health
Christoph Vetten, Head of Transactions Animal Health, shares his perspectives on how building successful collaborations can drive innovation.
Reimagining digital healthcare worldwide
How does our digital lab BI X innovate in Ingelheim and Shanghai? Read about success stories based on different ideation processes
Listen to the sounds disrupting farms worldwide
A pioneer in Precision Livestock Farming, Prof. Daniel Berckmans reveals how online monitoring technology is bringing healthier pigs closer to farmers and consumers
EHS management approach
We protect our employees, facilities and the environment from harmful influences, conserve natural resources and promote environmental awareness
Vaccine prevent calf diarrhea
Fencovis® is the first vaccine to prevent calf diarrhea caused by E. coli F5 and bovine rotavirus and reduce severity of calf diarrhea caused by bovine coronavirus
Partnering with Lifebit to detect global disease outbreaks
Boehringer Ingelheim partners with Lifebit to detect global infectious disease outbreaks
Digital solution for individualized diabetes care
With Exandra™, we have developed a clinical decision support tool for diabetes care to make everyday life easier for healthcare professionals.
Ingelheim
The company headquarters of Boehringer Ingelheim are located in Ingelheim, Germany.
garbage game
Learn more about marine pollution and find out how long it takes for garbage to dissolve in the oceans.
ArisGlobal acquires Boehringer Ingelheim technology
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
The GPP Charter
The GPP Charter defines a collaborative approach to identifying common goals for the GPP community
T-cell engagers: Reawakening T-cells to fight cancer
Learn how we are taking cancer on through our approach to immuno-oncology and our T-cell engagers plarform
Tomorrow's leaders
We invest in our employees by giving them leadership training that enhances their skills and prepares them for future roles within the organization.
Fornovo
With its production facilities, Fornovo San Giovanni constitutes an important site for the production of core active pharmaceutical ingredients for both Human Pharma and Animal Health.
About Office Hours
Boehringer Ingelheim Office Hours mentors early-stage life-science companies providing access to expertise, an industry perspective and feedback.
Cardiometabolic Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in CardioMetabolic diseases.
Ethical Business Practices
Suppliers shall conduct their business in an ethical manner and act with integrity.
empa-reg-outcome-recurrent-events
EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease
Boehringer Ingelheim becomes member of IPC
Boehringer Ingelheim becomes member of IPC Boehringer Ingelheim is proud to join the International Poultry Council thus reaffirming its strong long-term commitment to shaping the future of poultry health. The International Poultry Council represents a uni
Partnership to further develop pet market in China
Boehringer Ingelheim invests in partnership to further develop the pet market in China, acquires a stake in New Ruipeng Group
Circular economy
Boehringer Ingelheim strives to use resources for as long as possible, process them for reuse or recycle them.